|
1
|
Yu E, Calvert PA, Mercer JR, Harrison J,
Baker L, Figg NL, Kumar S, Wang JC, Hurst LA, Obaid DR, et al:
Mitochondrial DNA damage can promote atherosclerosis independently
of reactive oxygen species through effects on smooth muscle cells
and monocytes and correlates with higher-risk plaques in humans.
Circulation. 128:702–712. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mercer JR: Mitochondrial bioenergetics and
therapeutic intervention in cardiovascular disease. Pharmacol Ther.
141:13–20. 2014. View Article : Google Scholar
|
|
3
|
Dikalov SI and Nazarewicz RR: Angiotensin
II-induced production of mitochondrial reactive oxygen species:
potential mechanisms and relevance for cardiovascular disease.
Antioxid Redox Signal. 19:1085–1094. 2013. View Article : Google Scholar :
|
|
4
|
Queliconi BB, Wojtovich AP, Nadtochiy SM,
Kowaltowski AJ and Brookes PS: Redox regulation of the
mitochondrial K(ATP) channel in cardioprotection. Biochim Biophys
Acta. 1813:1309–1315. 2011. View Article : Google Scholar :
|
|
5
|
Dikalov S: Cross talk between mitochondria
and NADPH oxidases. Free Radic Biol Med. 51:1289–1301. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Doughan AK, Harrison DG and Dikalov SI:
Molecular mechanisms of angiotensin II-mediated mitochondrial
dysfunction: linking mitochondrial oxidative damage and vascular
endothelial dysfunction. Circ Res. 102:488–496. 2008. View Article : Google Scholar
|
|
7
|
Wang H, Zhang Y, Xia T, Wei W, Chen F, Guo
X and Li X: Synergistic promotion of blood vessel regeneration by
astragaloside IV and ferulic acid from electrospun fibrous mats.
Mol Pharm. 10:2394–2403. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ko JK, Lam FY and Cheung AP: Amelioration
of experimental colitis by Astragalus membranaceus through
anti-oxidation and inhibition of adhesion molecule synthesis. World
J Gastroenterol. 11:5787–5794. 2005.PubMed/NCBI
|
|
9
|
Yang J, Wang HX, Zhang YJ, Yang YH, Lu ML,
Zhang J, Li ST, Zhang SP and Li G: Astragaloside IV attenuates
inflammatory cytokines by inhibiting TLR4/NF-κB signaling pathway
in isoproterenol-induced myocardial hypertrophy. J Ethnopharmacol.
150:1062–1070. 2013. View Article : Google Scholar
|
|
10
|
Gui D, Huang J, Guo Y, Chen J, Chen Y,
Xiao W, Liu X and Wang N: Astragaloside IV ameliorates renal injury
in streptozotocin-induced diabetic rats through inhibiting
NF-κB-mediated inflammatory genes expression. Cytokine. 61:970–977.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu W, Shao X, Tian L, Gu L, Zhang M, Wang
Q, Wu B, Wang L, Yao J, Xu X, et al: Astragaloside IV ameliorates
renal fibrosis via the inhibition of mitogen-activated protein
kinases and antiapoptosis in vivo and in vitro. J Pharmacol Exp
Ther. 350:552–562. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu X, Cao Y, Nie J, Liu H, Lu S, Hu X, Zhu
J, Zhao X, Chen J, Chen X, et al: Genetic and pharmacological
inhibition of Rheb1-mTORC1 signaling exerts cardioprotection
against adverse cardiac remodeling in mice. Am J Pathol.
182:2005–2014. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang WD, Zhang C, Wang XH, Gao PJ, Zhu
DL, Chen H, Liu RH and Li HL: Astragaloside IV dilates aortic
vessels from normal and spontaneously hypertensive rats through
endothelium-dependent and endothelium-independent ways. Planta Med.
72:621–626. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yin Y, Qi F, Song Z, Zhang B and Teng J:
Ferulic acid combined with astragaloside IV protects against
vascular endothelial dysfunction in diabetic rats. Biosci Trends.
8:217–226. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao Z, Wang W, Wang F, Zhao K, Han Y, Xu
W and Tang L: Effects of Astragaloside IV on heart failure in rats.
Chin Med. 4:62009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu XL, Ji H, Gu SY, Shao Q, Huang QJ and
Cheng YP: Modification of alterations in cardiac function and
sarcoplasmic reticulum by astragaloside IV in myocardial injury in
vivo. Eur J Pharmacol. 568:203–212. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Qiu LH, Xie XJ and Zhang BQ: Astragaloside
IV improves homocysteine-induced acute phase endothelial
dysfunction via antioxidation. Biol Pharm Bull. 33:641–646. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sun L, Li W, Li W, Xiong L, Li G and Ma R:
Astragaloside IV prevents damage to human mesangial cells through
the inhibition of the NADPH oxidase/ROS/Akt/NF-κB pathway under
high glucose conditions. Int J Mol Med. 34:167–176. 2014.PubMed/NCBI
|
|
19
|
Sun Q, Jia N, Wang W, Jin H, Xu J and Hu
H: Protective effects of astragaloside IV against amyloid beta1-42
neurotoxicity by inhibiting the mitochondrial permeability
transition pore opening. PLoS One. 9:e988662014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hu JY, Han J, Chu ZG, Song HP, Zhang DX,
Zhang Q and Huang YS: Astragaloside IV attenuates hypoxia-induced
cardiomyocyte damage in rats by upregulating superoxide dismutase-1
levels. Clin Exp Pharmacol Physiol. 36:351–357. 2009. View Article : Google Scholar
|
|
21
|
Tu L, Pan CS, Wei XH, Yan L, Liu YY, Fan
JY, Mu HN, Li Q, Li L, Zhang Y, et al: Astragaloside IV protects
heart from ischemia and reperfusion injury via energy regulation
mechanisms. Microcirculation. 20:736–747. 2013.PubMed/NCBI
|
|
22
|
Shen Y, Tian Y, Yang J, Shi X, Ouyang L,
Gao J and Lu J: Dual effects of carnosine on energy metabolism of
cultured cortical astrocytes under normal and ischemic conditions.
Regul Pept. 192–193:45–52. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mukhopadhyay P, Rajesh M, Haskó G, Hawkins
BJ, Madesh M and Pacher P: Simultaneous detection of apoptosis and
mitochondrial superoxide production in live cells by flow cytometry
and confocal microscopy. Nat Protoc. 2:2295–2301. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Laurindo FR, de Souza HP, Pedro MA and
Janiszewski M: Redox aspects of vascular response to injury.
Methods Enzymol. 352:432–454. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Herst PM and Berridge MV: Cell surface
oxygen consumption: a major contributor to cellular oxygen
consumption in glycolytic cancer cell lines. Biochim Biophys Acta.
1767:170–177. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xie H, Lev D, Gong Y, Wang S, Pollock RE,
Wu X and Gu J: Reduced mitochondrial DNA copy number in peripheral
blood leukocytes increases the risk of soft tissue sarcoma.
Carcinogenesis. 34:1039–1043. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Elahi MM, Kong YX and Matata BM: Oxidative
stress as a mediator of cardiovascular disease. Oxid Med Cell
Longev. 2:259–269. 2009. View Article : Google Scholar
|
|
28
|
Wei Y, Clark SE, Thyfault JP, Uptergrove
GM, Li W, Whaley-Connell AT, Ferrario CM, Sowers JR and Ibdah JA:
Oxidative stress-mediated mitochondrial dysfunction contributes to
angiotensin II-induced nonalcoholic fatty liver disease in
transgenic Ren2 rats. Am J Pathol. 174:1329–1337. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Prathapan A, Vineetha VP and Raghu KG:
Protective effect of Boerhaavia diffusa L. against mitochondrial
dysfunction in angiotensin II induced hypertrophy in H9c2
cardiomyoblast cells. PLoS One. 9:e962202014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schulz E, Wenzel P, Munzel T and Daiber A:
Mitochondrial redox signaling: Interaction of mitochondrial
reactive oxygen species with other sources of oxidative stress.
Antioxid Redox Signal. 20:308–324. 2014. View Article : Google Scholar :
|
|
31
|
Lijnen PJ, van Pelt JF and Fagard RH:
Downregulation of manganese superoxide dismutase by angiotensin II
in cardiac fibroblasts of rats: Association with oxidative stress
in myocardium. Am J Hypertens. 23:1128–1135. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Touyz RM: Reactive oxygen species and
angiotensin II signaling in vascular cells - implications in
cardiovascular disease. Braz J Med Biol Res. 37:1263–1273. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kimura S, Zhang GX, Nishiyama A, Shokoji
T, Yao L, Fan YY, Rahman M and Abe Y: Mitochondria-derived reactive
oxygen species and vascular MAP kinases: comparison of angiotensin
II and diazoxide. Hypertension. 45:438–444. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zablocki D and Sadoshima J: Angiotensin II
and oxidative stress in the failing heart. Antioxid Redox Signal.
19:1095–1109. 2013. View Article : Google Scholar :
|
|
35
|
Bedard K and Krause KH: The NOX family of
ROS-generating NADPH oxidases: physiology and pathophysiology.
Physiol Rev. 87:245–313. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Suematsu N, Tsutsui H, Wen J, Kang D,
Ikeuchi M, Ide T, Hayashidani S, Shiomi T, Kubota T, Hamasaki N and
Takeshita A: Oxidative stress mediates tumor necrosis
factor-alpha-induced mitochondrial DNA damage and dysfunction in
cardiac myocytes. Circulation. 107:1418–1423. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li H, Horke S and Förstermann U: Oxidative
stress in vascular disease and its pharmacological prevention.
Trends Pharmacol Sci. 34:313–319. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Qi W, Niu J, Qin Q, Qiao Z and Gu Y:
Astragaloside IV attenuates glycated albumin-induced
epithelial-to-mesenchymal transition by inhibiting oxidative stress
in renal proximal tubular cells. Cell Stress Chaperones.
19:105–114. 2014. View Article : Google Scholar
|
|
39
|
Wang YY, Peng Y, Zhang Q, Wu YN, Song JQ
and Liu YX: Effect of ERK1/2 signaling pathway on astragaloside IV
protects H9c2 cells against H2O2-induced
oxidative injury. Zhongguo Ying Yong Sheng Li Xue Za Zh.
27:363–367. 2011.In Chinese.
|
|
40
|
Mammucari C and Rizzuto R: Signaling
pathways in mitochondrial dysfunction and aging. Mech Ageing Dev.
131:536–543. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lee J, Giordano S and Zhang J: Autophagy,
mitochondria and oxidative stress: cross-talk and redox signalling.
Biochem J. 441:523–540. 2012. View Article : Google Scholar :
|
|
42
|
Narendra DP and Youle RJ: Targeting
mitochondrial dysfunction: role for PINK1 and Parkin in
mitochondrial quality control. Antioxid Redox Signal. 14:1929–1938.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kageyama Y, Hoshijima M, Seo K, Bedja D,
Sysa-Shah P, Andrabi SA, Chen W, Höke A, Dawson VL, Dawson TM, et
al: Parkin-independent mitophagy requires Drp1 and maintains the
integrity of mammalian heart and brain. EMBO J. 33:2798–2813. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Deng H, Dodson MW, Huang H and Guo M: The
Parkinson's disease genes pink1 and parkin promote mitochondrial
fission and/or inhibit fusion in Drosophila. Proc Natl Acad Sci
USA. 105:14503–14508. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang Y, Nartiss Y, Steipe B, McQuibban GA
and Kim PK: ROS-induced mitochondrial depolarization initiates
PARK2/PARKIN-dependent mitochondrial degradation by autophagy.
Autophagy. 8:1462–1476. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Scarpulla RC, Vega RB and Kelly DP:
Transcriptional integration of mitochondrial biogenesis. Trends
Endocrinol Metab. 23:459–466. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wu Z, Puigserver P, Andersson U, Zhang C,
Adelmant G, Mootha V, Troy A, Cinti S, Lowell B, Scarpulla RC and
Spiegelman BM: Mechanisms controlling mitochondrial biogenesis and
respiration through the thermogenic coactivator PGC-1. Cell.
98:115–124. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Biala A, Tauriainen E, Siltanen A, Shi J,
Merasto S, Louhelainen M, Martonen E, Finckenberg P, Muller DN and
Mervaala E: Resveratrol induces mitochondrial biogenesis and
ameliorates Ang II-induced cardiac remodeling in transgenic rats
harboring human renin and angiotensinogen genes. Blood Press.
19:196–205. 2010. View Article : Google Scholar : PubMed/NCBI
|
